drugset / Trial / NCT01161472
A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects
RandomizedCrossoverQuadruple-blind
Summary
The study is designed to evaluate elements of cognitive function in subjects receiving either fesoterodine or alprazolam.
Timeline
- Start
- 2010-07
- Primary completion
- 2010-09
- Completion
- 2010-09
Outcome
Missed primary endpoint
registry Fesoterodine 4 mg vs Placebo; p = 0.1198; Least square (LS) Mean Difference -0.0285 (95% CI -0.0647 to 0.0077); ANCOVA NCT01161472 ↗
registry Fesoterodine 8 mg vs Placebo; p = 0.2459; LS Mean Difference -0.0203 (95% CI -0.0551 to 0.0145); ANCOVA NCT01161472 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alprazolam | Small molecule | 1 mg | — |
| Subject | Fesoterodine | Other / unclassified | 4 mg | — |
| Subject | Fesoterodine | Other / unclassified | 8 mg | — |
Indications
No indication recorded.